*The search scope is limited to the products and news section of this site
*The search scope is limited to the products and news section of this site
Recently, the award ceremony for the "Henan Socially Responsible Enterprise of 2022 and Entrepreneur with Outstanding Social Contribution" was grandly held in Zhengzhou. Genuine Biotech was honored with the "2022 Annual Award of Henan Socially Responsible Enterprise".
Recently, researchers from Shanghai uploaded a preprint to the preprint server medRxiv. Among severely and critically ill patients with COVID-19 who received one or more therapeutic interventions, treatment with Azvudine had a 99.8% probability of improving 2-month survival compared with the control.
On May 12, the high-profile BEYOND Awards 2023 ceremony was held in Macao. After comprehensive consideration of multiple dimensions such as technical level, commercial value, and innovation value by the expert panel, the COVID-19 Oral Drug Azvudine won the BEYOND Awards Life Science Innovation Award.
On Apr. 19, Wan Yuanhao and He Binyuan, vice presidents of Genuine Biotech, made a team visit to the Third People's Hospital of Shenzhen (hereinafter referred to as the "TPHSZ") and had in-depth conversations with Prof. Lu Hongzhou, president of the hospital and a fellow of American Academy of Microbiology. In hope of satisfying unmet global clinical needs with safer and more efficient treatment options, both parties agreed to seek closer cooperation in the antiviral field.
Recently, the People's Government of Henan Province released the Decisions on Science and Technology Awards of Henan Province. The project "Development and Application of Azvudine for the Treatment of COVID-19" won the first prize of Henan Provincial Technical Invention Award.
Statistically, as of Feb. 28, 2023, Genuine Biotech, together with Shanghai Fosun Pharmaceutical (Group) Co., Ltd., has donated nearly 300,000 bottles of Azvudine Tablets to China's rural areas through the Shanghai Fosun Foundation, covering 250 cities and counties in Anhui, Yunnan, Guizhou, Henan, Gansu, Xinjiang, Tibet, Heilongjiang, Guangdong provinces, and Shanghai, with the coverage beyond expectation.
On Jan. 18, 2023, the press conference on the adjustment of the national reimbursement drug list announced that Azvudine tablets was officially included in the national reimbursement drug list.
The Expert Consensus is concise, practical, and highly operable. Hopefully it will improve the understanding of antiviral therapy for clinicians and provide suggestions for standardized medication in treatment of COVID-19.
On Jan. 9, 2023, Genuine Biotech, together with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "Fosun Pharma"), donated 100 million yuan's worth of oral drug for COVID-19, Azvudine, to rural areas in China through the Shanghai Fosun Foundation (hereinafter referred to as "Fosun Foundation"). The medicines will be donated in several phases to rural areas in Midwestern China, covering 180 counties.
On Jan. 6, 2023, the General Office of the National Health Commission and the General Department of the National Administration of Traditional Chinese Medicine released the Diagnosis and Treatment Guideline for COVID-19 (Tentative 10th Edition), and Azvudine Tablets is the only Chinese oral small-molecule drug for the treatment of COVID-19 recommended.
Copyright © 2022 河南真实生物科技有限公司 All Rights Reserved 京ICP备2021026784号-1
